Jonathan P. Piccini mostly deals with Atrial fibrillation, Internal medicine, Stroke, Cardiology and Warfarin. The various areas that Jonathan P. Piccini examines in his Atrial fibrillation study include Prospective cohort study, Heart failure, Embolism and Intensive care medicine. Jonathan P. Piccini focuses mostly in the field of Internal medicine, narrowing it down to matters related to Surgery and, in some cases, Radiology.
His Stroke research includes elements of Risk assessment, Rivaroxaban, Gastrointestinal bleeding and Clinical endpoint. His study in Rivaroxaban is interdisciplinary in nature, drawing from both Gastroenterology, Anesthesia, Framingham Risk Score and Renal function. His Warfarin study incorporates themes from Anticoagulant, Quartile and Incidence.
Internal medicine, Atrial fibrillation, Cardiology, Stroke and Heart failure are his primary areas of study. His work in the fields of Internal medicine, such as Hazard ratio, Myocardial infarction, Proportional hazards model and Ablation, intersects with other areas such as In patient. His Atrial fibrillation study combines topics from a wide range of disciplines, such as Embolism and Intensive care medicine.
Jonathan P. Piccini combines subjects such as Interquartile range and Clinical trial with his study of Cardiology. The concepts of his Stroke study are interwoven with issues in Prospective cohort study, Randomized controlled trial, Surgery, Lower risk and Cohort. His Warfarin research integrates issues from Anticoagulant, Anesthesia and Renal function.
Jonathan P. Piccini spends much of his time researching Internal medicine, Atrial fibrillation, Cardiology, Catheter ablation and Heart failure. His study in Internal medicine focuses on Cohort, Proportional hazards model, Ventricular tachycardia, Confidence interval and Hazard ratio. In the subject of general Atrial fibrillation, his work in Warfarin is often linked to In patient, thereby combining diverse domains of study.
His study in Catheter ablation is interdisciplinary in nature, drawing from both Cardiomyopathy, Emergency department and Left atrial. His research investigates the link between Heart failure and topics such as Clinical trial that cross with problems in Medical physics. In his study, which falls under the umbrella issue of Stroke, Obstructive sleep apnea is strongly linked to Myocardial infarction.
The scientist’s investigation covers issues in Atrial fibrillation, Internal medicine, Cardiology, Heart failure and Catheter ablation. The Atrial fibrillation study combines topics in areas such as Stroke, mHealth, Quality of life and Heart Rhythm. His study looks at the relationship between Stroke and topics such as Myocardial infarction, which overlap with Obstructive sleep apnea and Risk factor.
His work in the fields of Cardiology, such as Ventricular pacemaker, Cardiac tamponade and Myocardial perfusion imaging, overlaps with other areas such as Clinical Practice. His research in Heart failure intersects with topics in University hospital, Clinical trial, Clinical course and Intensive care medicine. His Cohort research incorporates elements of Hazard ratio and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel;Kenneth W. Mahaffey;Jyotsna Garg;Guohua Pan.
The New England Journal of Medicine (2011)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Keith A. A. Fox;Jonathan P. Piccini;Daniel Wojdyla;Richard C. Becker.
European Heart Journal (2011)
Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”
Jonathan P. Piccini;Susanna R. Stevens;YuChiao Chang;Daniel E. Singer.
Arrhythmogenic Right Ventricular Dysplasia A United States Experience
Darshan Dalal;Khurram Nasir;Chandra Bomma;Kalpana Prakasa.
Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
Douglas L. Packer;Daniel B. Mark;Richard A. Robb;Kristi H. Monahan.
Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007
Jonathan P. Piccini;Bradley G. Hammill;Moritz F. Sinner;Paul N. Jensen.
Circulation-cardiovascular Quality and Outcomes (2012)
Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials
Jonathan P. Piccini;Renato D. Lopes;Melissa H. Kong;Vic Hasselblad.
Circulation-arrhythmia and Electrophysiology (2009)
Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L. Halperin;Graeme J. Hankey;Daniel M. Wojdyla;Jonathan P. Piccini.
Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration
Ben Freedman;John Camm;Hugh Calkins;Jeffrey S Healey.
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
Jonathan P. Piccini;Susanna R. Stevens;Yuliya Lokhnygina;Manesh R. Patel.
Journal of the American College of Cardiology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: